Frontlight ResearchEarly access
Amyloidosis trials in United States
39 of 69 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma
- Where
- Atlanta, Denver
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00 - Phase 3Taking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Atlanta, Aurora, Austin, Baltimore, Boston, Brandon, Charleston, Charlotte, Charlottesville, Chicago, Cleveland, Columbus, Dallas, Detroit, Evanston, Falls Church, Gainesville, Houston, Indianapolis, Kansas City, Laguna Hills, La Jolla, Lancaster, Manhasset, Miami, New York, Norfolk, Norwich, Philadelphia, Plano, Portland, Richmond, Rochester, Salt Lake City, Seattle, Spokane, Stanford, St Louis, The Bronx, Tucker, Washington D.C.
- Age
- 18 years to 85 years
- People
- 2,250 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - No phaseTaking peopleElevated Rate Pacing of Cardiac Amyloidosis
- Where
- Minneapolis
- Age
- 18 years and over
- People
- 10
- Run by
- University of Minnesota
See details and how to joinNCT07583823 - Phase 3Taking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Ann Arbor, Atlanta, Baltimore, Boston, Charleston, Chicago, Cleveland, Columbus, Dallas, Denver, Detroit, Durham, Falls Church, Houston, Indianapolis, Jacksonville, Kansas City, Lexington, Los Angeles, Madison, New Haven, New York, Palo Alto, Philadelphia, Pittsburgh, Plano, Portland, Richmond, Rochester, San Diego, Tucson, Washington D.C., Weston
- Age
- 18 years to 90 years
- People
- 1,200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - Phase 1Taking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Charlotte, Denver, Duarte, Houston, Irvine, New York, Philadelphia, San Francisco
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
- Where
- Aurora, Boston, Hackensack, Los Angeles, Nashville, New Haven, Rochester, Salt Lake City
- Age
- 18 years to 64 years
- People
- 60 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07224672 · EU 2025-522803-60-00 - Early phase 1Not yet taking people in United StatesA Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
- Where
- Palo Alto
- Age
- 18 years and over
- People
- 5
- Run by
- Stanford University
See details and how to joinNCT07615270 - Phase 3Enrolling by invitationA Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Baltimore, Beverly Hills, Boston, Chicago, Cleveland, Columbus, Dallas, Durham, Glenview, Indianapolis, Kansas City, La Jolla, Nashville, New York, Omaha, Philadelphia, Phoenix, Rochester, Salt Lake City, Stanford, St Louis, Washington D.C.
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06679946 - Phase 3Taking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Abington, Allentown, Ann Arbor, Austin, Baltimore, Boston, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Detroit, Durham, Falls Church, Farmington Hills, Gainesville, Glenview, Greenville, Hershey, Honolulu, Houston, Indianapolis, Kansas City, La Jolla, Lancaster, Los Angeles, Manhasset, Murray, Nashville, New Haven, New Orleans, New York, Norfolk, Omaha, Orange, Pasadena, Philadelphia, Phoenix, Plano, Portland, Richmond, Rochester, Rosedale, San Francisco, Santa Rosa, Spokane, Stanford, St Louis, The Bronx, Tupelo, Washington D.C.
- Age
- 18 years and over
- People
- 1,280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - Phase 3Taking peopleTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Aurora, Baltimore, Boston, Chapel Hill, Chicago, Dallas, Houston, Nashville, New York, Rochester
- Age
- 18 years to 85 years
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - Phase 2Taking peopleDaratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
- Where
- Rochester, Scottsdale
- Age
- 18 years and over
- People
- 96
- Run by
- Mayo Clinic
See details and how to joinNCT05898646 - Phase 2Taking peopleThe Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Where
- Jacksonville
- Age
- 18 years and over
- People
- 27
- Run by
- Mayo Clinic
See details and how to joinNCT07285044 - No phaseTaking peoplePrevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
- Where
- Boston
- Age
- 65 years and over
- People
- 515
- Run by
- Massachusetts General Hospital
See details and how to joinNCT05577819 - Phase 3Not yet taking people in United StatesAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Atlanta, Aurora, Boston, Chapel Hill, Charleston, Cleveland, Columbus, Danville, Durham, Falls Church, Fort Worth, Greenville, Houston, Indianapolis, Irvine, Jacksonville, Kansas City, La Jolla, Madison, Memphis, New York, Palo Alto, Philadelphia, Portland, Richmond, Salt Lake City, San Francisco, Seattle, St Louis, Stony Brook, Washington D.C., Weston
- People
- 1,180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - Phase 4Taking peopleUltrasound Therapy In Cardiac Amyloidosis
- Where
- Boston
- Age
- 18 years to 90 years
- People
- 70
- Run by
- Brigham and Women's Hospital
See details and how to joinNCT04667494 - Phase 1/2Taking peoplePhase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
- Where
- Dallas, Nashville, Salt Lake City
- Age
- 18 years and over
- People
- 37
- Run by
- University of Texas Southwestern Medical Center
See details and how to joinNCT05145816 - Phase 1/2Taking peopleElranatamab in Patients With Relapsed or Refractory AL Amyloidosis
- Where
- Boston, Cleveland, New Haven
- Age
- 18 years and over
- People
- 49
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT06569147 - Phase 1/2Taking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Boston, Buffalo, Columbus, Denver, Detroit, Duarte, Houston, Nashville
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - Phase 1Enrolling by invitationPET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis
- Where
- St Louis
- Age
- 18 years and over
- People
- 50
- Run by
- Washington University School of Medicine
See details and how to joinNCT07771621 - Phase 2Not yet taking people in United StatesDose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
- Where
- Cleveland, Rochester
- Age
- 18 years and over
- People
- 64
- Run by
- Case Comprehensive Cancer Center
See details and how to joinNCT07524634 - Phase 3Taking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Atlanta, Aurora, Austin, Baltimore, Boston, Charleston, Chicago, Cleveland, Dallas, Detroit, Durham, Falls Church, Greenville, Jacksonville, Kansas City, La Jolla, Los Angeles, Miami, New Brunswick, New Haven, New York, Philadelphia, Pittsburgh, Portland, Richmond, Rochester, Rosedale, Salt Lake City, San Francisco, Seattle, Stanford, St Louis, Washington D.C., Weston
- Age
- 18 years to 75 years
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - Phase 4Taking peopleCardiac Magnetic Resonance and Echocardiography Study With Acoramidis
- Where
- St Louis
- Age
- 18 years to 80 years
- People
- 150 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07695701 · EU 2026-526068-19-00 - Phase 1Taking peopleA Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
- Where
- Knoxville
- Age
- 18 years and over
- People
- 31
- Run by
- University of Tennessee Graduate School of Medicine
See details and how to joinNCT05951816 - No phaseEnrolling by invitationAI Echocardiographic Screening of Cardiac Amyloidosis
- Where
- Chicago, Los Angeles, Palo Alto, Portland
- Age
- 22 years and over
- People
- 500
- Run by
- Cedars-Sinai Medical Center
See details and how to joinNCT06664866 - No phaseTaking peopleCAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
- Where
- Charlotte
- Age
- 18 years and over
- People
- 50
- Run by
- Wake Forest University Health Sciences
See details and how to joinNCT06096675